The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.
Novacyt has stopped recording revenues from a SARS-CoV-2 test supply deal with the UK Department of Health and Social Care until their dispute is settled.
The companies are focused on the development and manufacturing of microfluidic cartridges and blister reagent packages.
Last week, readers were most interested in funding provided by the US Department of Defense to companies for COVID-19 rapid antigen tests.
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
The RT-PCR-based test was developed by Northeastern University's Life Sciences Testing Center.
The agency is requiring test developers to monitor emerging mutations and their potential impact on the performance of authorized SARS-CoV-2 tests.
The funding will support OraSure's efforts to obtain 510(k) clearance and CLIA waiver for the InteliSwab rapid SARS-CoV-2 antigen test.
The test will be designed in both laboratory-based and point-of-care formats to address the needs of clinical and field settings.
The proposed "High Impact Phenotype Identification System" aims to reduce time to diagnosis of 13 high-impact genetic conditions.